Global H1N1 Vaccines Market Analysis
The H1N1 influenza virus causes swine flu, a viral illness that mostly affects the respiratory system. Infection with the H1N1 strain is the hallmark of swine flu. Temperature, cold, sore throat, runny or stuffy nostrils, watery and blurry vision, joint pain, migraine, tiredness, and diarrhea are all symptoms of the H1N1 virus. H1N1 is transmitted through inhaling airborne contaminants or visiting affected geographical areas. Infection with H1N1 can exacerbate other chronic respiratory diseases including bronchitis, pneumonia, COPD, and even death from respiratory failure.
Since 2009, the H1N1 vaccine has been a significant invention in the fight against the H1N1 pandemic. Initially, the only vaccinations that had been produced or were accessible were inactivated monovalent vaccines that could protect against infection from most H1N1 strains. Inactivated vaccines are administered intra-dermally, whereas live attenuated vaccines are administered intra-nasally. These methods have a similar effectiveness profile and are bioequivalent in terms of preventing H1N1. Several international pharmaceutical firms and companies from developing countries compete in the global H1N1 vaccination market.
Growing illness frequency and pandemic events caused by H1N1 infection are one of the key factors driving the H1N1 market forward. According to the World Health Organization’s (WHO) 2018 data, 290,000 to 650,000 fatalities from all forms of influenza infection are recorded each year (including Influenza A i.e. H1N1). The same report included that there are 3 to 5 million instances of severe sickness caused by viral influenza infection per year.
Federal measures to combat the H1N1 pandemic, both worldwide and domestically, would have a beneficial influence on market growth. Health organizations such as the World Health Organization (WHO) have played a key role in producing vaccinations and ensuring that they are distributed efficiently. Following the 2009 H1N1 influenza pandemic, the U.S. government launched a US$ 3 billion H1N1 vaccine initiative, in which it hired five large businesses to produce H1N1 vaccines. The National Influenza Centers and WHO Collaborating Centers are actively checking influenza viruses prevalent in people as part of the WHO’s Global Influenza Surveillance and Response System, which changes the formulation of influenza vaccinations twice a year.
Ask for PDF sample copy of the H1N1 Vaccines market report @ https://www.coherentmarketinsights.com/insight/request-pdf/2056
Moreover, the growing elderly population throughout the world would provide another push for the global H1N1 vaccines market to expand. As per a 2017 UN report, the global population is reaching the age of 60 at a pace of 3% each year. Increased age increases the risk of different respiratory tract illnesses and immune weak conditions, increasing the chance of H1N1 virus infection. Patients’ increased awareness of preventative healthcare methods such as immunization may result in a larger demand for H1N1 vaccinations over the forecast period.
The changing nature of the H1N1 flu has resulted in low income for several of the major companies. Given the lack of demand, India’s Serum Institute, which develops an intranasal live vaccination to combat swine flu, had to destroy 2 million doses of stock in 2011. If a pandemic strikes quickly, vaccination supplies may be delayed owing to poor vaccine manufacture, putting people’s health at risk. Since this H1N1 virus is constantly changing, vaccinations may prove inadequate in some regions of the world, creating a hindrance for the growth of the global H1N1 vaccines market.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/2056
Over the forecast period, North America is projected to lead the global H1N1 vaccines market. This is owing to the government’s increased efforts to prevent H1N1 infection. In 2009, the U.S. was hit by a massive outbreak. Following the pandemic, the United States has implemented a vaccine campaign to enhance its preventative response to the H1N1 epidemic. As per figures released by the Centers for Disease Control and Prevention in February 2018, clinical laboratories tested 666,493 specimens for influenza virus between October 1, 2017 and February 3, 2018, with 124,316 (18.7%) of those testing positive. A total of 84.3 percent positively identified for influenza A.
Considering the high frequency of swine flu and rising knowledge about H1N1 vaccine, the Asia Pacific market is anticipated to grow at the fastest rate. Around 0.1 million occurrences of H1N1 influenza were reported in India between 2010 and 2017, according to the Ministry of Health and Family Welfare of the Government of India. The virus’s ever-changing nature makes it difficult to combat the H1N1 pandemic. In 2017, a new Michigan strain of H1N1 swine flu virus was discovered in India for the first time. The government has played a critical role in the fight against swine flu by raising knowledge about the H1N1 vaccination. The Indian government has released recommendations for the management of influenza A/H1N1 cases, which divide patients into three groups based on their severity.
Got any Query? Feel free to ask us at: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2056
Major companies contributing in the global H1N1 vaccines market include Abbott Healthcare, CSL Biotherapeutics, Novartis, GlaxoSmithKline, AstraZeneca, Medimmune, Lupin Ltd., Cadila Healthcare, ID Biomedical Corporation, Serum Institute of India, Sinovac, and Sanofi Pasture.
Main points in H1N1 Vaccines Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global H1N1 Vaccines Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: H1N1 Vaccines Industry Impact
Chapter 2 Global H1N1 Vaccines Competition by Types, Applications, and Top Regions and Countries
2.1 Global H1N1 Vaccines (Volume and Value) by Type
2.3 Global H1N1 Vaccines (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global H1N1 Vaccines Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America H1N1 Vaccines Market Analysis
Chapter 6 East Asia H1N1 Vaccines Market Analysis
Chapter 7 Europe H1N1 Vaccines Market Analysis
Chapter 8 South Asia H1N1 Vaccines Market Analysis
Chapter 9 Southeast Asia H1N1 Vaccines Market Analysis
Chapter 10 Middle East H1N1 Vaccines Market Analysis
Chapter 11 Africa H1N1 Vaccines Market Analysis
Chapter 12 Oceania H1N1 Vaccines Market Analysis
Chapter 13 South America H1N1 Vaccines Market Analysis
Chapter 14 Company Profiles and Key Figures in H1N1 Vaccines Business
Chapter 15 Global H1N1 Vaccines Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027